CurveBeam AI

**ASX: CVB**

**4 September 2026**

# Board Update – Director Resignation and Board Strengthening

Melbourne, Australia & Hatfield, Pennsylvania: CurveBeam AI Limited (ASX: CVB, "CurveBeam AI" or the "Company"), a fully integrated developer and manufacturer of point-of-care specialised medical imaging (CT) equipment, supported by a range of AI-enabled SaaS-based clinical assessment solutions, announces a number of changes to its board and governance.

**Hashan De Silva resignation as an NED**

Mr Hashan De Silva has resigned as a Non-Executive Director of the Company, effective 3rd September 2026.

Mr De Silva has served on the Board since September 2021 and has chaired the Remuneration and Nomination Committees during his tenure. The Board sincerely thanks Hashan for his contribution to the Company, particularly his public markets and financial expertise, which have been important during a strategically significant period of the Company's development. Mr De Silva founded his own investment fund in 2024, which invested in the Company shortly after founding. His commitments to his fund, along with the Board's desire to satisfy Corporate Governance Recommendations and appoint more independent Non-Executive Directors led to a mutual decision for Hashan's transition off the board following the FY26 reporting period.

The Chair of the Board, Rob Lilley, said:

"On behalf of the Board, I thank Hashan for his commitment to CurveBeam AI and the time he has dedicated to the Company over the past five years. Hashan brought a valuable public markets and institutional investor perspective to the Board, providing an important understanding of the expectations and considerations of the investment community. He was always willing to engage on the Company's strategy and was an advocate for understanding and communicating the Company's investment proposition. It has been a pleasure to have Hashan on the Board, and we wish him every success for the future."

**Dr Yu Peng appointed as Executive Director**

Further to Mr De Silva's resignation, the Company is pleased to advise that Dr Yu Peng has been appointed to the Board effective 3$^{rd}$ September 2026 as an Executive Director. Dr Peng is a senior technology leader of CurveBeam AI and brings extensive experience across AI, medical imaging technology, product development, engineering, and the application of advanced imaging technologies in clinical environments.

Dr Peng also brings a deep understanding of the Chinese healthcare and medical technology markets, including the commercial, cultural and relationship dynamics that are important to successfully developing the Company's strategic relationship with Wego Orthopaedics.

Telephone: +61 3 9620 0250
Email: info@curvebeamai.com
Website: curvebeamai.com

Corporate Office
Level 10, 10 Queen Street
Melbourne, Victoria, 3000, Australia

Global Operations Headquarters
2800 Bronze Dr., Suite 110
Hatfield, PA 19440 USA

CurveBeam AI Chair, Rob Lilley, said:

"Dr Peng brings a unique combination of deep technical knowledge, product leadership and international experience to the Board. His understanding of our technology and the Chinese market will be particularly valuable as we work with Wego to develop the significant opportunities available to CurveBeam AI in China. We believe his appointment will strengthen the connection between the Company's technology, product development and international commercial strategy."

**Further strengthening of Board expertise**

The Board has also progressed a formal process to identify and appoint an independent Non-Executive Director with the skills and experience to chair the Audit and Risk Committee and contribute to the Remuneration and Nomination Committee.

The Board has identified and considered several potential candidates and has commenced interviews. The search is focused on individuals with a combination of senior corporate, financial and capital markets experience, mergers and acquisitions and strategic transaction expertise, public company governance experience, and significant US and global orthopaedics commercialisation experience. This skill set is intended to complement the Company's existing Board capabilities and support CurveBeam AI as it transitions from a development-focused medical technology company towards a more commercially focused international growth strategy.

The Company expects to make a further announcement regarding the appointment within the near future.

Appointment of a fourth independent Non-Executive Director is targeted for later in FY2027 to satisfy the recommendations for an independent majority of four Non-Executive Directors.

The Board has also recently been strengthened by the appointment of Mr Patrick Fisher, who brings extensive global orthopaedics experience developed through senior roles with Wright Medical, Stryker and Orthofix. His industry knowledge and commercial perspective have already proved valuable to the Board.

The Chair, Rob Lilley, said:

"The Board is deliberately building a complementary mix of capabilities around technology, orthopaedics, international markets, governance, corporate finance and strategic growth. Patrick Fisher has already brought significant global orthopaedic industry experience to the Board, and the next independent appointment is intended to add another important dimension, combining senior corporate and financial expertise with a deep understanding of global medical technology commercialisation and strategic transactions."

The Company will provide further updates to the market regarding Board composition and any appointments as appropriate.

**Release has been authorised by the Board**

## About CurveBeam AI Limited

CurveBeam AI (ASX:CVB) develops, manufactures and sells specialised medical imaging (CT) scanners, coupled with AI SaaS-based clinical assessment solutions, to support medical practitioners in the management of musculoskeletal conditions. The Company's flagship CT scanner, HiRise™, performs weight bearing CT scans as well as traditional non weight bearing CT scans, providing a range of advantages over the use of traditional CT or MRI devices. CurveBeam AI has more than 70 employees with its corporate office, AI and IP functions located in Melbourne, VIC, Australia and global operations headquarters in Hatfield, Pennsylvania, USA.

For further information go to https://curvebeamai.com

## Investor / media enquiries

Matthew Wright
NWR Communications
+61 (0) 451 896 420
matt@nwrcommunications.com.au